Efficacy and relapse profiles of Pola‐R‐ CHP versus R‐ CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70280 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Toshiki Terao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, O…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
In this retrospective, multicentre cohort study, we compared the real‐world efficacy of polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin and prednisone (Pola‐R‐CHP) versus the conventional rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in 370 patients in the propensity score matching cohort from 1096 patients with previously untreated diffuse large B‐cell lymphoma (DLBCL) (pola; n = 185 in the matched and 356 in the full cohort). The analysis focused on clinical efficacy, the prognostic performance of established risk models and the relapse profiles with the chemotherapies. The Pola‐R‐CHP group showed superior 1‐year progression‐free survival (PFS) compared to the R‐CHOP group (86.7% vs. 73.5%, p = 0.027); however, the 1‐year overall survival (OS) was similar (92.8% vs. 89.6%, p = 0.24). Within the Pola‐R‐CHP group, the Central Nervous System International Prognostic Index (CNS‐IPI) effectively stratified the cumulative incidence of CNS relapse of 0%, 2.1% and 4.5% in the low, intermediate and high‐risk groups respectively ( p = 0.023). Additionally, the 1‐year incidence of nodal relapse was significantly lower in the Pola‐R‐CHP group than in the R‐CHOP group (2.1% vs. 10.9%, p = 0.013), whereas the incidence of extra‐nodal relapse remained similar (3.8% vs. 5.2%, p = 0.57). These findings underscore the clinical efficacy of Pola‐R‐CHP over R‐CHOP in first‐line DLBCL treatment. However, early extra‐nodal relapse and CNS relapse remained a therapeutic challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Hematology, Okayama University Hospital, Okayama, Japan.
- Lymphoma Working Group of the Okayama Hematology Study Group (OHSG), Okayama, Japan.
- Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
- Department of Hematology and Oncology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
- Department of Hematology and Blood Transfusion, Kochi Health Sciences Center, Kochi, Japan.
ORCID-Profile: Toshiki Terao, Hiroyuki Sugiura, Daisuke Ikeda
Zitieren
APA
Terao, T., Yoshida, I., Kobayashi, H., Urata, T., Fujii, F., Meguri, Y., Sugiura, H., Yoshioka, T., Saeki, K., Niiya, D., Asakura, S., Nishimori, H., Ikeda, D., Fujiwara, H., Ennishi, D., & Maeda, Y. (2026). Efficacy and relapse profiles of Pola‐R‐ CHP versus R‐ CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study. British Journal of Haematology. https://doi.org/10.1111/bjh.70280
Vancouver
Terao T, Yoshida I, Kobayashi H, Urata T, Fujii F, Meguri Y, et al. Efficacy and relapse profiles of Pola‐R‐ CHP versus R‐ CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study. British Journal of Haematology. 2026. doi:10.1111/bjh.70280
BibTeX
@article{Terao2026,
author = {Terao, Toshiki and Yoshida, Isao and Kobayashi, Hiroki and Urata, Tomohiro and Fujii, Fuminari and Meguri, Yusuke and Sugiura, Hiroyuki and Yoshioka, Takanori and Saeki, Kyosuke and Niiya, Daigo and Asakura, Shoji and Nishimori, Hisakazu and Ikeda, Daisuke and Fujiwara, Hideaki and Ennishi, Daisuke and Maeda, Yoshinobu},
title = {Efficacy and relapse profiles of Pola‐R‐ CHP versus R‐ CHOP in previously untreated diffuse large B‐cell lymphoma: A multicentre real‐world study},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70280}
}
EUVIMED